Evidence map›Paper›PMID 22948160›Full record

ArticleThe Journal of biological chemistry2012

TRIM56 is an essential component of the TLR3 antiviral signaling pathway.

Yang Shen, Nan L Li, Jie Wang, Baoming Liu, Sandra Lester, Kui Li

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. The regulation of innate antiviral immunity by TRIM56.Infectious diseases & immunity · 2025
    Review
  12. Review
  13. Pulmonary embolism in children with mycoplasma pneumonia: can it be predicted?European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Pulmonary microbial spectrum in late-stage SARS-CoV-2 infection: a case series.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  20. Review

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yang ShenDepartment of Microbiology, Immunology, and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.
Nan L Li
Jie Wang
Baoming Liu
Sandra Lester
Kui Li
University of Tennessee Health Science Center · US

Funding

Role of TLR3 Signaling in Control of HCVR01AI069285 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI LI, KUI · 2007 to 2016
$2.5M
Training Grant in Bacterial PathogenesisT32AI078906 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI BYRNE, GERALD IRWIN · 2009 to 2013
$339k
Role of TLR3 Signaling in Control of HCVR56AI069285 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LI, KUI · 2012 to 2012
$300k
NIAID NIH HHS AI069285NIAID NIH HHS R01 AI069285NIAID NIH HHS R56 AI069285NIAID NIH HHS T32 AI078906
6 · The paper itself

Abstract

Members of the tripartite motif (TRIM) proteins are being recognized as important regulators of host innate immunity. However, specific TRIMs that contribute to TLR3-mediated antiviral defense have not been identified. We show here that TRIM56 is a positive regulator of TLR3 signaling. Overexpression of TRIM56 substantially potentiated extracellular dsRNA-induced expression of interferon (IFN)-β and interferon-stimulated genes (ISGs), while knockdown of TRIM56 greatly impaired activation of IRF3, induction of IFN-β and ISGs, and establishment of an antiviral state by TLR3 ligand and severely compromised TLR3-mediated chemokine induction following infection by hepatitis C virus. The ability to promote TLR3 signaling was independent of the E3 ubiquitin ligase activity of TRIM56. Rather, it correlated with a physical interaction between TRIM56 and TRIF. Deletion of the C-terminal portion of TRIM56 abrogated the TRIM56-TRIF interaction as well as the augmentation of TLR3-mediated IFN response. Together, our data demonstrate TRIM56 is an essential component of the TLR3 antiviral signaling pathway and reveal a novel role for TRIM56 in innate antiviral immunity.

Indexed as

Immunity, InnateAdaptor Proteins, Vesicular TransportAmino Acid SequenceHEK293 CellsHeLa CellsHepacivirusHepatitis CHumansInterferon-betaInterferon Regulatory Factor-3Sequence DeletionSignal TransductionToll-Like Receptor 3Tripartite Motif ProteinsUbiquitin-Protein LigasesAdaptor Proteins, Vesicular TransportInterferon-betaInterferon Regulatory Factor-3IRF3 protein, humanTICAM1 protein, humanTLR3 protein, humanToll-Like Receptor 3TRIM56 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligases

Identifiers

PMID22948160
PMCPMC3476306
OpenAlexW2087708376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.